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The Wnt pathway plays an important role in developmentand in regulating adult stem cell systems. A variety of
cellular processes are mediated by Wnt signaling, including
proliferation, differentiation, survival, apoptosis and cell mo-
tility.1 Loss of regulation of these pathways can lead to
tumorigenesis and the Wnt pathway has been implicated in
the development of several types of cancers, including colon,
lung, leukemia, breast, thyroid, and prostate.2–6
WNT SIGNALING
Wnts are a family of secreted glycoproteins with vary-
ing expression patterns and a range of functions. Four sig-
naling pathways are typically described for Wnt proteins. The
canonical Wnt- catenin pathway, through which -catenin
dependent activity occurs, the polar cell polarity (PCP) path-
way, involving activation of AP1 through JNK, an atypical
receptor tyrosine kinase (RTK) pathway, and the Ca2
pathway, which activates protein kinase C and affects cell
adhesion.7 In the unstimulated canonical pathway, -catenin
is phosphorylated by glycogen synthase kinase (GSK-3) in a
complex that includes adenomatous polyposis coli (APC) and
axin.8 Phosphorylation targets -catenin for ubiquitin-medi-
ated degredation and results in decreased levels of cytosolic
-catenin (Table 1).
Binding by the Wnt ligant to the frizzled (Fzd) recep-
tors are complexed with low density lipoprotein receptor
related protein (LRP) resulting in inhibition of the GSK-3/
APC/Axin complex by Disheveled (Dvl). -catenin is not
phosphorylated by the complex and accumulates in the cyto-
plasm where it is translocated to the nucleus and regulates
gene expression through a complex with Tcf and Lef.7 In the
noncanonical pathways, signaling is conducted independent
of -catenin, though there may be similar components up-
stream of Fzd. The activity of different Wnt proteins is
dependent on the receptor context, making strict classifi-
cation of Wnts as canonical or noncanonical very chal-
lenging9 (Figure 1).
Fzd receptors are involved in canonical and noncanoni-
cal Wnt signaling by binding Wnt at a CRD region and have
been shown to specify downstream activity through G-pro-
teins. Binding of the LRP receptor to Fzd, however, occurs
only in the canonical pathway.10 Other Wnt pathway recep-
tors include atypical RTKs Ror and Ryk. Several ligands not
structurally related to Wnt also influence the Wnt signaling
pathway, including antagonists sFRP, DKK, SOST, and ago-
nists Norrin and R-spondin.11
WNT SIGNALING IN NORMAL LUNG
DEVELOPMENT
Wnt signaling appears to regulate cell fate and differ-
entiation in early embryogenesis through several components
that are present in the developing lung.12 Wnt production may
be specific to cell type, such as Wnt 2 in the mesenchyme,
Wnt 7b in the epithelium, and Wnt 11 in both locations.8 Wnt
7b has been shown to be regulated by Thyroid Transcription
Factor-1, which is important for differentiation of alveolar
epithelial cells.13 Other Wnt pathway components, such as
Frizzled and Tcf, have been detected in specific patterns in
the developing lung.14 Wnt 7b null mice have hypoplastic
lungs and impaired alveolar type I cell differentiation.15 Wnt
5a is expressed in the lung epithelium and mesenchyme early
development at the distal tips. Loss of Wnt 5a in mice results
in increased proliferation in the epithelium and mesenchymal
compartments, increased distal branching, and thickened in-
terstitium.16 Wnt 5a null mice have increased expression of
Sonic Hedgehog, a tightly regulated protein involved in
branching morphogenesis, suggesting that Wnt 5a interacts
with other signaling pathways in lung development. How-
ever, a model using targeted deletion of -catenin suggests
that disruption of Wnt signaling leads to decreased branching
morphogenesis.17 Continued study is needed to clarify the
role of Wnt signaling in branching morphogenesis. Wnt
signaling may also play a role in apical-basal polarity and
organogenesis, as changes in expression of polarity complex
components have been found to affect Wnt signaling and the
Wnt pathway itself may affect apical basal polarity.18
WNT SIGNALING AND LUNG CANCER
Much of the research done on the Wnt pathway and
cancer has been done in colon tumors, however, recent work
highlights a potentially significant role for Wnt pathway
components in lung cancer. Wnt 1 and Wnt 2 are overex-
pressed in NSCLC and their inhibition leads to apoptosis.19
*Department of Medicine, University of Colorado at Denver and Health
Sciences Center (UCDHSC); and †Veterans Administration Medical
Center, Denver, Colorado
Address for correspondence: Robert A. Winn, MD, Division of Pulmonary
and Critical Care Medicine, University of Colorado at Denver and Health
Sciences Center 4200 E. Ninth Ave., Denver, CO 80262, Phone: (303)
315-0011, Fax: (303) 315-0470; Email: robert.winn@uchsc.edu
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0210-0889
Journal of Thoracic Oncology • Volume 2, Number 10, October 2007 889
Wnt 7a is of particular interest, as its re-expression has been
reported to lead to growth inhibition of NSCLC cell lines
through ERK5-dependent activation of Peroxisome Prolifera-
tor-Activated Receptor Gamma.20,21 This pathway seems to
be required for the maintenance of normal epithelial differ-
entiation and represents noncanonical signaling by the Wnt
pathway.
Disheveled proteins are overexpressed in NSCLC and
are a route for Wnt/Fzd activation of Rac and Rho, which are
known to be involved in lung carcinogenesis.22 WIF-1, an
antagonist of Wnt signaling, is silenced by promoter methyl-
ation in NSCLC and is able to inhibit cell growth in vitro and
in vivo.23 APC and sFRP1 are also methylated in lung
adenocarcinoma, often concomitantly with WIF-1.24 Evalua-
tion of chromosomal aberrations and changes in gene expres-
sion in NSCLC found that WIF1, CTNNBIP1, and WISP2
(antagonists of the Wnt pathway) were underexpressed and
LEF1 and Ruvbl1 (agonists) were overexpressed.25 DKK1,
an antagonist of Wnt signaling, is expressed in NSCLC cell
lines, while sFRPs are downregulated.22,26 These findings
suggest roles for Wnt pathway components in tumorigenesis,
though more work is needed to clarify the biological effects
of pathway disruption.
WNT SIGNALING PATHWAY AS A
THERAPEUTIC TARGET
The Wnt pathway may play a significant role in lung
tumor initiation and progression, thus providing opportunities
for therapeutic intervention. Therapuetic interference with the
Wnt pathway could be conducted at several levels. Restora-
tion of SFRP4 function in cancer cells weakens Wnt signaling
and induces apoptosis in NSCLC cell lines.27 Interference
with Wnt 1 signaling by siRNA or antibody induces apoptosis
in cancer cells and inhibits tumor growth in vivo.28 siRNA for
TABLE 1. Dysregulation of Wnt Pathway in Cancer
Pathway Component Type of Cancer
Increased Wnt-1 Prostate,32 Head and Neck,33 Breast34
Increased Wnt-2 Breast35
Decreased Wnt5a Colorectal,36 Neuroblastoma,37 Thyroid,38
Breast39
Increased Wnt7a Colorectal,40 Gastric,40 Endometrial,41
Decreased Wnt7a Lung20,42
Increased DVL Breast,4 Lung,30 Mesothelioma30
Increased LRP5/LRP6 Colorectal43
Increased Fzd2 Gastric44
Increased Fzd3 Leukemia45
Increased Fzd5 Kidney46
Increased Fzd7 Liver47
Increased Fzd8 Gastric44
Increased Fzd9 Astrocytoma,48 Gastric44
Decreased sFRP Liver,49 Breast,4 Bladder,50 Head and Neck,51
Leukemia,52 Mesothelioma,53 Colorectal54
Increased DVL Breast,4 Lung,30 Mesothelioma55
Decreased APC Gastrointestinal,56 Breast,57 Kidney58
Decreased Axin Oral,59 Liver,60 Lung61
Increased -catenin Ovarian,62 Hepatoblastoma,63 Kidney64
Fzd, Frizzled; DVL, Disheveled; LRP, sFRP, Secreted Frizzled-Related Protein;
APC, Adenomatous Polyposis Coli.
FIGURE 1. Wnt/-catenin signal-
ing. (A). Canonical pathway. (B).
Noncanonical pathway.
APC, adenomatous polyposis coli;
Dvl, disheveled; GSK3, glycogen
synthase kinase; Fzd, Frizzled; TCF,
T-cell factor; LEF, lymphoid en-
hancer factor; JNK, c-jun N-termi-
nal kinase; PCK, protein kinase C;
CamK, calmodulin kinase II.
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Wnt 2 downregulates -catenin and induces apoptosis in
NSCLC.29 Restoration of Wnt 7a expression has been shown
to reverse transformation in NSCLC and may be one ap-
proach to therapy through Wnt signaling.20 Reduction of
Disheveled overexpression by siRNA leads to a decrease in
-catenin expression and Tcf transcription activity in
NSCLC.30 A small molecule inhibitor, ICG-001, antagonizes
-catenin/Tcf transcription activation and downregulates
-catenin/Tcf responsive genes.31
The Wnt pathway, along with the Hedgehog pathway,
is activated by smoke in bronchial epithelial cells and treat-
ment with Sulindac, a Wnt pathway specific inhibitor, re-
sulted in decreased tumor mass and volume in mice.31 This
may be an opportunity for inhibition of early stage tumori-
genesis in the lungs of smokers. Proper apical/basal polarity
has been implicated in cell cycle control and cell-cell adhe-
sion, both processes disrupted in tumorigenesis, and as the
role of Wnt signaling in this process is clarified, interventions
in this pathway that lead to restoration of apical basal polarity
may be therapeutic options.18
Investigations into the role of Wnt signaling in the lung
have clearly begun to elucidate the importance of this path-
way in lung cancer, however, there is still much to be done.
The participation of different Wnt proteins in different path-
ways complicates the determination of the effects of changes
in Wnt expression, as does the presence of many levels of
regulation along the pathway. The diversity of Wnt signaling,
however, provides a bounty of opportunity for development
of desperately needed targeted therapy for lung cancer.
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